Lipid PL40
Instructions for Use
Product information
PL40 is a cardiolipin-mimic phosphoramide (CAMP) lipid developed for antibody-free, T-cell-favored mRNA delivery. The cited study reported approximately 100-fold higher luciferase expression than ALC-0315 LNP and MessengerMax in primary human T cells under a specific in vitro assay, more than 80% GFP-positive human T cells at tested doses of at least 0.5 micrograms per 100,000 cells, and spleen-favored expression after intravenous administration. PL40 LNPs carrying circular uPAR CAR mRNA were also evaluated in preclinical liver-fibrosis and collagen-induced-arthritis models. All formulation and performance information shown below is literature-derived study evidence, not a product specification or a guarantee of reproducible LNP performance.
| CAS No. | Not available |
| Chemical Name | Lipid PL40 |
| Formula | C86H170N4O14P2 |
| M.Wt | 1,546.27 |
| Purity | ELSD-HPLC>95% |
| Storage | Original product: up to 1 year under the storage conditions stated on the vial, kept tightly sealed. Stock solutions: aliquots at -20°C, generally up to one month. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
Formulation & study context
Literature information refers to the cited study and its particular formulation. Administration routes are research context, not clinical instructions or a guarantee of performance.
| Component | mol% | Role |
|---|---|---|
| PL40 | Not reported | Ionizable lipid |
| DOPE | Not reported | Helper phospholipid |
| Cholesterol | Not reported | Sterol |
| DMG-PEG2000 | Not reported | PEG lipid |
| Reported total | Not reported | Source values retained |
| N/P ratio | Not reported in the cited article |
| Total lipid:cargo weight ratio | Not reported in the supplied main article or Supporting Information |
| Buffer & pH | 10 mM citrate aqueous phase, pH 4; final dialysis into PBS at 4 degrees C overnight |
| Cargo | Linear or circular luciferase mRNA, depending on the experiment |
| Administration route | Intravenous tail-vein injection |
| Dose | 0.25 mg mRNA/kg for the reported luciferase-expression study |
| Animal model | C57BL/6 mice |
| Formulation process | Aqueous mRNA and ethanolic lipids were combined at 3:1 v/v by hand mixing or microfluidic mixing. Final mRNA concentration was 0.1 mg/mL; the article does not assign one mixing mode or report device and flow settings for every experiment. |
N/P is the molar ratio of specified lipid nitrogen groups to nucleic-acid phosphate groups. A lipid:cargo mass ratio is a different quantity and must not be used as N/P.
Stock-solution preparation table
Calculated from the product-page molecular weight: 1546.27 g/mol. Volumes are final solution volumes.
| Lipid mass | 1 mM | 5 mM | 10 mM |
|---|---|---|---|
| 10 mg | 6.467 mL | 1.293 mL | 0.647 mL |
| 25 mg | 16.168 mL | 3.234 mL | 1.617 mL |
| 50 mg | 32.336 mL | 6.467 mL | 3.234 mL |
| 100 mg | 64.672 mL | 12.934 mL | 6.467 mL |
| 250 mg | 161.679 mL | 32.336 mL | 16.168 mL |
Volume (mL) = mass (mg) × 1000 / [MW (g/mol) × concentration (mM)]. These are mathematical conversions, not measured solubility or validated solvent recommendations. Confirm solvent compatibility and the molecular weight of the exact material before use.
Open editable solution calculators →Handling & storage
Provided that storage conditions are as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 1 year.
Wherever possible, prepare and use solutions on the same day. If stock solutions must be prepared in advance, store them as aliquots in tightly sealed vials at -20°C. Generally, these will be usable for up to one month.
Before use, and prior to opening the vial, allow the product to equilibrate to room temperature for at least 1 hour.
References
Cited literature for this formulation and performance dataset Zhang Z, Ma B, Li B, et al. Cardiolipin-mimic lipid nanoparticles without antibody modification delivered senolytic in vivo CAR-T therapy for inflamm-aging. Cell Reports Medicine. 2025;6:102209. DOI: 10.1016/j.xcrm.2025.102209 Structure: main Figures 1E and 2D; formulation and preparation: main Results and STAR Methods p. e4; particle properties: main Figure 2E; T-cell transfection, circRNA expression and preclinical efficacy: main Figures 1-7 and Supplementary Figures S1-S21.